Corcept Therapeutics Incorporated (NASDAQ:CORT) received a Buy rating with a $145 price target from H.C. Wainwright analyst Swayampakula Ramakanth. The stock dropped due to Curant Rare becoming a distributor for Korlym, replacing Optime Care. Ramakanth sees this as a temporary setback and recommends buying on weakness. Corcept focuses on cortisol-related therapies, with Korlym approved for Cushing’s syndrome.

While Corcept (CORT) has potential, some AI stocks offer greater upside with less risk. For a promising AI investment, check out the best short-term AI stock. Find more stock recommendations like 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now on Insider Monkey. No disclosures.

Read more at Yahoo Finance: H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)